.png)
.png)
Latest news from BIA
Pharmaceutical industry responds to Trade Bill amendment on medicines
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
Joint statement from BIA/ABPI on EU Council meeting
At the end of June's EU Council meeting, Steve Bates, chief executive of the BIA and Mike Thompson, chief executive of the ABPI said:
BIA responds to new government investment to attract world's best in science and innovation
The BIA has to responded to the announcement from government of the inaugural UKRI Future Leaders Fellowship Scheme will receive £900 million over the next 11 years. BIA CEO Steve Bates said: “Today’s announcement will help to boost innovation in the UK and I am delighted to see that businesses will be able to use this scheme. It is vital that the UK government continues to support young entrepreneurs and business leaders to secure the innovation pipeline in the UK for the future.”
BIA welcomes new £2.5bn fund for innovative UK businesses
The BIA welcomes the creation of British Patient Capital, a £2.5 billion fund launched today by the British Business Bank. The fund will provide long-term funding to support the growth of innovative UK bioscience companies and other sectors.
Accelerate@Babraham Start-up Competition: Winners Announced
Five science start-ups have been awarded £20k and access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham
Positive Top Line Data from the CARE CF 1 Clinical Study of Oral Lynovex in Cystic Fibrosis Exacerbations
NovaBiotics, the clinical stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases, this morning announces its oral therapy for cystic fibrosis, Lynovex®, has met the study objectives of the CARE CF 1 clinical trial.
Minister of State Sam Gyimah MP to open Schrödinger Building at The Oxford Science Park
Oxford, UK, July 5 2018 - The state-of-the-art Schrödinger Building at The Oxford Science Park, one of the UK's leading parks for science and technology companies, is to be opened this afternoon by Sam Gyimah MP, Minister of State for Universities, Science, Research & Innovation.
Arecor successfully defends a key Europan Polysaccharide Vaccine Patent in its opposition proceedings
Cambridge, UK., 3rd July 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals and vaccines via its innovative formulation technology, continues to add to its strong patent portfolio protecting the Company’s proprietary Arestat™ technology and product assets.
Home Office reports use of animals in science statistics for 2017
Each year, the Home Office publishes statistics relating to regulated scientific procedures that are carried out on protected living animals in Great Britain. The reports give statistics on experimental procedures carried out on animals as well as on the creation and breeding of genetically altered animals. The report also covers what types of animals are used, and what quantities of each are used.
Video of the week: BIA CEO Steve Bates on BBC Newsnight
What might a no-deal Brexit mean for pharmaceutical companies in the UK? What might it mean for patients and businesses? BIA CEO spoke to BBC Newsnight's Helen Thomas about the implications of Brexit on our sector. Two BIA members also features; AstraZeneca and Quay.
CEO Update: Monday 16 July
A big thank you to all of the BIA members who joined our 18th annual Parliament Day last Thursday. Despite the event falling in what has been a tumultuous week for Westminster, it proved a roaring success. The day was most enjoyable and effective and had the added twist of the government releasing their White Paper on Brexit in the middle of it. The paper was largely positive for our sector, with significant detail on a proposed future relationship on medicine regulation, aligning with the key points we have been consistently advocating for two years. In terms of science and innovation and R&D funding, the UK proposes a “science and innovation accord” which will provide for UK participation in EU research funding programmes.
Video of the week: AstraZeneca Cancer Research UK (CRUK) – MedImmune Alliance Laboratory
Cancer Research UK and MedImmune have teamed up and formed a lab which is focused on studying oncology, and improving the science of fighting cancer. Scientists from CRUK and MedImmune work alongside eachother in the CMAL lab, with the aim of taking one of the projects to the status of nominated agent in a clinic within five years of work in the lab.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
